| pubmed-article:9311865 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9311865 | lifeskim:mentions | umls-concept:C0019372 | lld:lifeskim |
| pubmed-article:9311865 | lifeskim:mentions | umls-concept:C0003451 | lld:lifeskim |
| pubmed-article:9311865 | lifeskim:mentions | umls-concept:C0123759 | lld:lifeskim |
| pubmed-article:9311865 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:9311865 | lifeskim:mentions | umls-concept:C0015272 | lld:lifeskim |
| pubmed-article:9311865 | lifeskim:mentions | umls-concept:C1517004 | lld:lifeskim |
| pubmed-article:9311865 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:9311865 | pubmed:dateCreated | 1997-10-20 | lld:pubmed |
| pubmed-article:9311865 | pubmed:abstractText | The prophylactic and therapeutic efficacy of interleukin-12 was studied by using murine models of herpes simplex virus infection. Prophylactic administration consisted of two intraperitoneal doses of interleukin-12 given 48 and 24 h prior to infection. Therapeutic intraperitoneal administration of interleukin-12 commenced 6 h after the mice were infected with herpes simplex virus and was continued daily for a total of 5 days. Interleukin-12 therapy improved the survival rates of mice with systemic herpes simplex virus infection compared with those of placebo-treated infected mice. Subcutaneous administration of interleukin-12 also improved the rate of survival of mice after systemic herpes simplex virus infection, although higher doses were required to give comparable effects. Combined prophylactic and therapeutic administration of interleukin-12 produced the greatest effect on survival after an otherwise lethal systemic infection. Intraperitoneal administration of interleukin-12 for 2 days before and 3 days after systemic infection with herpes simplex virus resulted in survival of 80% of the mice. These surviving mice were resistant to subsequent reinfection with herpes simplex virus. Such resistance was apparently specific for herpes simplex virus infection, since a second group of survivors succumbed to a lethal infection with murine cytomegalovirus. Infectious virus was recovered from lumbar ganglia explants dissected from survivors of prophylactic interleukin-12 therapy and cultured for 5 days in vitro, suggesting that interleukin-12 treatment did not prevent the establishment of latent herpes simplex virus infection. One action of interleukin-12 may be to enhance natural killer cell-mediated clearance of the virus. However, interleukin-12 therapy was also effective in mice carrying the beige mutation, which reduces natural killer cell lytic activity, suggesting that interleukin-12 has additional activities in vivo. | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9311865 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9311865 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9311865 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9311865 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:9311865 | pubmed:issn | 0022-538X | lld:pubmed |
| pubmed-article:9311865 | pubmed:author | pubmed-author:BoothR FRF | lld:pubmed |
| pubmed-article:9311865 | pubmed:author | pubmed-author:CarrJ AJA | lld:pubmed |
| pubmed-article:9311865 | pubmed:author | pubmed-author:RobertsN ANA | lld:pubmed |
| pubmed-article:9311865 | pubmed:author | pubmed-author:MulqueenM JMJ | lld:pubmed |
| pubmed-article:9311865 | pubmed:author | pubmed-author:RogersonJJ | lld:pubmed |
| pubmed-article:9311865 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9311865 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:9311865 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9311865 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9311865 | pubmed:pagination | 7799-803 | lld:pubmed |
| pubmed-article:9311865 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:meshHeading | pubmed-meshheading:9311865-... | lld:pubmed |
| pubmed-article:9311865 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9311865 | pubmed:articleTitle | Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections. | lld:pubmed |
| pubmed-article:9311865 | pubmed:affiliation | Virology Department, Roche Development Welwyn, Welwyn Garden City, Hertfordshire, United Kingdom. | lld:pubmed |
| pubmed-article:9311865 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9311865 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9311865 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9311865 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9311865 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9311865 | lld:pubmed |
